The first moAb anti-EGFR approved was cetuximab (ErbituxTM) used in clinical practice in combination with chemotherapy for RAS wild-type advanced colorectal cancer (CRC) and with radiotherapy or chemotherapy for locally advanced patients unfit for platinum, and for recurrent/metastatic patients, without PD-L1 expression, with head and neck squamous cell carcinoma (HNSCC), respectively (Baselga et al., 2000). This evidence concerns the gene EGFR and colorectal carcinoma.